120 related articles for article (PubMed ID: 3931565)
1. Reversible inhibition of central precocious puberty with a long acting GnRH analogue.
Ward PS; Ward I; McNinch AW; Savage DC
Arch Dis Child; 1985 Sep; 60(9):872-4. PubMed ID: 3931565
[TBL] [Abstract][Full Text] [Related]
2. Gonadotrophin responses to GnRH in precocious puberty treated with GnRH analogue.
Donaldson MD; Stanhope R; Lee TJ; Price DA; Brook CG; Savage DC
Clin Endocrinol (Oxf); 1984 Nov; 21(5):499-503. PubMed ID: 6437705
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of GnRH analogue (Buserelin) treatment in girls with central precocious puberty.
Brauner R; Thibaud E; Bischof P; Sizonenko PC; Rappaport R
Acta Paediatr Scand; 1985 Nov; 74(6):945-9. PubMed ID: 3937430
[TBL] [Abstract][Full Text] [Related]
4. The treatment of central precocious puberty using an intranasal LHRH analogue (buserelin).
Stanhope R; Adams J; Brook CG
Clin Endocrinol (Oxf); 1985 Jun; 22(6):795-806. PubMed ID: 3926352
[TBL] [Abstract][Full Text] [Related]
5. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
[TBL] [Abstract][Full Text] [Related]
6. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).
Bourguignon JP; Van Vliet G; Vandeweghe M; Malvaux P; Vanderschueren-Lodeweyckx M; Craen M; Du Caju MV; Ernould C
Eur J Pediatr; 1987 Nov; 146(6):555-60. PubMed ID: 3123239
[TBL] [Abstract][Full Text] [Related]
7. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
Luder AS; Holland FJ; Costigan DC; Jenner MR; Wielgosz G; Fazekas AT
J Clin Endocrinol Metab; 1984 Jun; 58(6):966-72. PubMed ID: 6427266
[TBL] [Abstract][Full Text] [Related]
8. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
[TBL] [Abstract][Full Text] [Related]
9. [Monitoring the treatment of precocious puberty with a GnRH-analog (buserelin): comparison of the GnRH-test with nocturnal pulsatility of LH, testosterone and 17-beta-estradiol].
Radetti G; Pasquino B; Castellan C; Gentili L; Mengarda G
Pediatr Med Chir; 1991; 13(5):471-4. PubMed ID: 1788106
[TBL] [Abstract][Full Text] [Related]
10. LH-RH agonistic analog (buserelin) treatment of precocious puberty: collaborative study in Japan.
Suwa S; Hibi I; Kato K; Nakazima H
Acta Paediatr Jpn; 1988; 30 Suppl():176-84. PubMed ID: 3146872
[No Abstract] [Full Text] [Related]
11. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
[TBL] [Abstract][Full Text] [Related]
12. Precocious puberty due to a lipid-cell tumour of the ovary.
Dengg K; Fink FM; Heitger A; Tabarelli M; Kreczy A; Glatzl J; Berger H
Eur J Pediatr; 1993 Jan; 152(1):12-4. PubMed ID: 8444198
[TBL] [Abstract][Full Text] [Related]
13. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist.
Tuvemo T; Gustafsson J; Proos LA;
Horm Res; 2002; 57(1-2):27-31. PubMed ID: 12006716
[TBL] [Abstract][Full Text] [Related]
14. Irreversible increase of serum IGF-1 and IGFBP-3 levels in GnRH-dependent precocious puberty of different etiologies: implications for the onset of puberty.
Belgorosky A; Rivarola MA
Horm Res; 1998; 49(5):226-32. PubMed ID: 9568807
[TBL] [Abstract][Full Text] [Related]
15. Serum bioactive follicle-stimulating hormone levels in girls with precocious sexual development.
Wang C; Zhong CQ; Leung A; Low LC
J Clin Endocrinol Metab; 1990 Mar; 70(3):615-9. PubMed ID: 2106526
[TBL] [Abstract][Full Text] [Related]
16. Treatment of central precocious puberty with an LHRH agonist (Buserelin): effect on growth and bone maturation after three years of treatment.
Rappaport R; Fontoura M; Brauner R
Horm Res; 1987; 28(2-4):149-54. PubMed ID: 2969858
[TBL] [Abstract][Full Text] [Related]
17. Growth, growth hormone and sex steroid secretion in girls with central precocious puberty treated with a gonadotrophin releasing hormone (GnRH) analogue.
Stanhope R; Pringle PJ; Brook CG
Acta Paediatr Scand; 1988 Jul; 77(4):525-30. PubMed ID: 3293348
[TBL] [Abstract][Full Text] [Related]
18. A Gonadotropin-Releasing Hormone (GnRH) Stimulation Test Before and After GnRH Analogue Treatment for Central Precocious Puberty: Has the GnRH Test been Adequately Simplified?
Kim MS; Hwang PH; Lee DY
Indian J Pediatr; 2015 Nov; 82(11):996-1000. PubMed ID: 25956950
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
Marcondes JA; Abujamra AC; Minanni SL; Mendonca BB; Nery M; Lerario AC; Pereira MA; Abelin N; Wajchenberg BL
Horm Metab Res; 1993 Feb; 25(2):105-9. PubMed ID: 8458605
[TBL] [Abstract][Full Text] [Related]
20. Thelarche variant: a new syndrome of precocious sexual maturation?
Stanhope R; Brook CC
Acta Endocrinol (Copenh); 1990 Nov; 123(5):481-6. PubMed ID: 2124026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
